Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
On January 12, 2026, Novartis secured exclusive global rights to an undisclosed peptide-based radioligand therapy asset from Zonsen PepLib Biotech, a Chinese company based in Zhuzhou, Hunan.
The deal includes a $50 million upfront payment to PepLib, plus potential milestone payments and royalties on future sales.
Novartis will handle all future research, development, and commercialization of the asset, which targets precision cancer treatment by delivering radiation directly to tumor cells.
PepLib specializes in peptide discovery for cancer and cardiovascular diseases and was founded in 2017.
The agreement strengthens Novartis' oncology pipeline, leveraging its expertise in radioligand therapies.